Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LumOnate: 177Lu-PSMA-I&T + Olaparib + Pembrolizumab in mCRPC
NCT07090369Phase 1Withdrawn
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu 177 PSMA I&T, olaparib and pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Progression Free Survival at 24 months and Safety of Combination Therapy at 24 months. Planned start Nov 2025; status: withdrawn.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07090369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090369.